Palifermin: AMJ 9701, KGF - Amgen, recombinant human keratinocyte growth factor, rHu-KGF

Drugs in R and D

Volumn 5, Issue 6, 2004, Pages 351-354

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMJ 9701; AMYLASE; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; KERATINOCYTE GROWTH FACTOR; MELPHALAN; PLACEBO; RECOMBINANT KERATINOCYTE GROWTH FACTOR; TRIACYLGLYCEROL LIPASE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IRELAND; LYMPHOMA; META ANALYSIS; MOUSE; MOUTH DISEASE; NONHUMAN; PRIORITY JOURNAL; SCANDINAVIA; SKIN DISEASE; SKIN EDEMA; SKIN TINGLING; SORE THROAT; STOMATITIS; SYSTEMATIC REVIEW; UNITED STATES; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; GRAFT REJECTION; HUMANS; MICE; MOUTH DISEASES; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 10244256297     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405060-00008     Document Type: Article

References (9)

1. Durrant S, Pico JL, Schmitz N, et al. A phase I study of recombinant human keratinocyte growth factor in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Blood 94 (Suppl. 1): 708, Part 1, 15 Nov 1999
2. Meropol NJ, Gutheil J, Pelley R, et al. Keratinocyte growth factor as a mucositis protectant: a randomized phase I trial. 36th Annual Meeting of the American Society of Clinical Oncology 19: 603, 20 May 2000
3. Amgen Inc. Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources. Media Release: 9 Dec 2003. Available from URL: http://www.amgen.com
4. Amgen Inc. Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients. Media Release: 1 Jun 2003. Available from URL: http://www.amgen.com
5. Panoskaltsis-Mortari A, Lacey DL, Vallera DA. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92: 3960-3967, 15 Nov 1998
6. Amgen. Amgen's KGF shows preliminary efficacy in preventing chemotherapy-induced severe oral mucositis. Media Release [4 pages]: 14 May 2001. Available from URL: http://www.amgen.com
7. Amgen. Amgen Announces Positive Results of Phase 3 Study for rHu-KGF. Media Release: 23 Jan 2003. Available from URL: http://www.amgen.com
8. Stiff P, Bensinger W, Emmanouilides C, et al. Treatment of mucositis with palifermin improves patient function and results in a clinically meaningful reduction in mouth and throat soreness: phase 3 results. Blood 102: 194, No. 11, Part 1, 16 Nov 2003
9. Emmanouilides C, Spielberger R, Stiff P, et al. Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results. Blood 102: 251-252, No. 11, Part 1, 16 Nov 2003